ERYTECH Pharma (NASDAQ: ERYP) has received a Fast Track designation from the US FDA  for eryspase for treating acute lymphocytic leukemia (ALL) patients that have developed E. coli—derived pegylated asparaginase hypersensitivity. Eryaspase demonstrated promising results in ALL patients  CEO Gil Beyen said, “This is yet another significant milestone and meaningful […]